A resident of Greenwich, Connecticut, Marc Wolpers is a business and finance graduate dedicated to learning about cancer due to family history. Marc Wolpers stays informed and promotes cancer research and awareness by participating in the Damon Runyon Cancer Research Foundation events.
The Damon Runyon Cancer Research Foundation was founded in 1946 to advance discoveries and understand cancer while also developing innovative prevention, diagnosis, and treatment approaches. On April 5, 2021, Damon Runyon published a news article on their website announcing that former Damon Runyon-Rachleff Innovator Nicholas E. Navin, Ph.D., has distinguished between healthy cells and malignant cells in several solid tumors with 98 percent accuracy.
Along with his colleagues at MD Anderson Cancer Center, Nicholas E. Navin, Ph.D. used a new computational approach called copy number karyotyping of aneuploid tumors (CopyKAT) to make this distinction. The innovative method now allows the indistinct mass of heterogeneous cells that is the tumor to gain a single-cell resolution. CopyKAT enables medical doctors to distinguish between cancer and normal cells and analyze the genetic diversity within cancer cell populations. The increased precision in tumor sample analysis translates to patients benefiting from earlier detection and better prognostics.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.